Imatinib Mesylate is a multitargeted c-kit, PDGF-R and c-ABL inhibitor with IC50 of 3.9 and 2.9 ¦ÌM for the inhibition of T-cell proliferation stimulated by DCs and PHA, respectively. A reversible tyrosine kinase inhibitor effective in treatment of chronic myelogenous leukemia1 (CML), gastrointestinal stromal tumors, eosinophilic disorders, and systemic mast cell disease. Imatinib Mesylate binds preferentially to ATP¨Cbinding sites of the c-kit protooncogene product, platelet-derived growth factor receptor (PDGF-R), and Abelson kinase (c-ABL) impeding the ensuing signal transduction.

June 21, 2017

prudect name : Imatinib Mesylate is a multitargeted c-kit, PDGF-R and c-ABL inhibitor with IC50 of 3.9 and 2.9 ¦ÌM for the inhibition of T-cell proliferation stimulated by DCs and PHA, respectively. A reversible tyrosine kinase inhibitor effective in treatment of chronic myelogenous leukemia1 (CML), gastrointestinal stromal tumors, eosinophilic disorders, and systemic mast cell disease. Imatinib Mesylate binds preferentially to ATP¨Cbinding sites of the c-kit protooncogene product, platelet-derived growth factor receptor (PDGF-R), and Abelson kinase (c-ABL) impeding the ensuing signal transduction.
Imatinib mesylate

Synonyms: CAS NO: 220127-57-1Molecular Formula: C₂₉H₃₁N₇O.CH₄O₃SMolecular Weight: 589.71Purity: 99%Solubility: In DMSOStorage: -20°C

PD 0332991 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18519681